20(R)-Ginsenoside Rg3CAS# 38243-03-7 |
- Ginsenoside Rg3
Catalog No.:BCN1068
CAS No.:14197-60-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 38243-03-7 | SDF | Download SDF |
| PubChem ID | 46887680 | Appearance | White powder |
| Formula | C42H72O13 | M.Wt | 785.02 |
| Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
| Solubility | DMSO : 41.67 mg/mL (53.08 mM; Need ultrasonic) | ||
| Chemical Name | (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-2-[[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-12-hydroxy-17-[(2R)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol | ||
| SMILES | CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(C(O6)CO)O)O)O)C)C)O)C)O)C | ||
| Standard InChIKey | RWXIFXNRCLMQCD-CZIWJLDFSA-N | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 20(R)-Ginsenoside Rg3 has anticarcinogenic, neuroprotective, anti-aging and antifatigue activities, it has a wide spectrum of targets including caspase-3, MMP-2, MMP-9,HIF-1α,VEGF,IL-1,IL-6 and TNF-α. |
| Targets | VEGFR | MMP(e.g.TIMP) | FLT3 | SOD | Bcl-2/Bax | Caspase | Akt | PI3K | HIF | TNF-α | IL Receptor |
| In vitro | The inhibition of 20(R)-ginsenoside Rg3 on the expressions of angiogenesis factors proteins in human lung adenocarcinoma cell line A549 and HUVEC304 cell.[Pubmed: 15806969]Zhongguo Zhong Yao Za Zhi. 2005 Mar;30(5):357-60.To study the effect of 20(R)-Ginsenoside Rg3 on the expressions of angiogenesis factors proteins (VEGF,bFGF, MMP-2) in human lung adenocarcinoma cell line A549 and HUVEC304 cell. 20(R)-Ginsenoside Rg3 protects SH-SY5Y cells against apoptosis induced by oxygen and glucose deprivation/reperfusion.[Pubmed: 28709827 ]Bioorg Med Chem Lett. 2017 Aug 15;27(16):3867-3871.As shown in our previous studies, 20(R)-Ginsenoside Rg3 [20(R)-Rg3] exerts a neuroprotective effect on a rat model of transient focal cerebral ischemia, and the mechanism through which it decreases the mRNA expression of calpain I and caspase-3 has been delineated. However, researchers do not know whether 20(R)-Rg3 exhibits a neuroprotective effect following oxygen-glucose deprivation and reperfusion (OGD/R) injury in vitro. |
| In vivo | The anti-fatigue effect of 20(R)-ginsenoside Rg3 in mice by intranasally administration.[Pubmed: 18981567]Biol Pharm Bull. 2008 Nov;31(11):2024-7.20(R)-Ginsenoside Rg3 (20(R)-Rg3) has shown multiple pharmacological activities and been considered as one of the most promising approaches for fatigue treatment. However, 20(R)-Ginsenoside Rg3 has a low bioavailability after oral administration in human due to the first-pass effect. Recently, nasal route has gained increasing interest as it can avoid first-pass effect for its lower enzymatic activity compared with the gastrointestinal tract and liver. In order to provide an animal experimental evidence of 20(R)-Ginsenoside Rg3 intranasal administrated preparation, the anti-fatigue effect of 20(R)-Ginsenoside Rg3 after intranasal administration was investigated. |
| Kinase Assay | Studies of 20(R)-ginsenoside Rg3 on Reversal Multidrug Resistance (MDR) and Induction of Apoptosis in K562/ADM Cell Line[Reference: WebLink]Effects of 20(R)-Ginsenoside Rg3on Apoptosis of Human Glioma U87 Cells.[Reference: WebLink]Journal of Chengdu Medical College,2014,9(1) :4-7To examine the effects of 20(R)-Ginsenoside Rg3on apoptosis of human glioma U87 cells. Progress of Anatomical Sciences,2002, 8(1):31-35.To observe and study the mechanism of reversing multidrug resistance (MDR) of K562/ADM cell line by a new anti plasma drug 20(R)-Ginsenoside Rg3. |
20(R)-Ginsenoside Rg3 Dilution Calculator
20(R)-Ginsenoside Rg3 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.2739 mL | 6.3693 mL | 12.7385 mL | 25.4771 mL | 31.8463 mL |
| 5 mM | 0.2548 mL | 1.2739 mL | 2.5477 mL | 5.0954 mL | 6.3693 mL |
| 10 mM | 0.1274 mL | 0.6369 mL | 1.2739 mL | 2.5477 mL | 3.1846 mL |
| 50 mM | 0.0255 mL | 0.1274 mL | 0.2548 mL | 0.5095 mL | 0.6369 mL |
| 100 mM | 0.0127 mL | 0.0637 mL | 0.1274 mL | 0.2548 mL | 0.3185 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- beta-Amyrenonol
Catalog No.:BCN5436
CAS No.:38242-02-3
- Enhydrin chlorohydrin
Catalog No.:BCN4639
CAS No.:38230-99-8
- Anhydroicaritin
Catalog No.:BCN5351
CAS No.:38226-86-7
- Filixic acid ABA
Catalog No.:BCN6330
CAS No.:38226-84-5
- Pyroxamide
Catalog No.:BCC2424
CAS No.:382180-17-8
- Coumarin VI
Catalog No.:BCN7833
CAS No.:38215-36-0
- Bacopaside II
Catalog No.:BCC8125
CAS No.:382146-66-9
- Adrenosterone
Catalog No.:BCC4061
CAS No.:382-45-6
- Sulindac
Catalog No.:BCC4861
CAS No.:38194-50-2
- 7,8-Dihydroxyflavone
Catalog No.:BCC6072
CAS No.:38183-03-8
- Bephenium Hydroxynaphthoate
Catalog No.:BCC3735
CAS No.:3818-50-6
- 28-Hydroxy-3-oxoolean-12-en-29-oic acid
Catalog No.:BCN1449
CAS No.:381691-22-1
- Malonomicin
Catalog No.:BCN1844
CAS No.:38249-71-7
- Glucose-conjugated MGMT inhibitor
Catalog No.:BCC1597
CAS No.:382607-78-5
- Burchellin
Catalog No.:BCN6676
CAS No.:38276-59-4
- Naringenin trimethyl ether
Catalog No.:BCN5437
CAS No.:38302-15-7
- Minoxidil
Catalog No.:BCC4297
CAS No.:38304-91-5
- YE 120
Catalog No.:BCC6188
CAS No.:383124-82-1
- 3-O-beta-D-Glucopyranosylplatycodigenin
Catalog No.:BCN7832
CAS No.:38337-25-6
- Homovanillic Acid Sulfate
Catalog No.:BCN2226
CAS No.:38339-06-9
- UC 112
Catalog No.:BCC8042
CAS No.:383392-66-3
- Neuropeptide W-23 (human)
Catalog No.:BCC5961
CAS No.:383415-79-0
- Taxinine
Catalog No.:BCN6944
CAS No.:3835-52-7
- 3',4'-Anhydrovinblastine
Catalog No.:BCN2392
CAS No.:38390-45-3
[Anticarcinogenic effect of 20(R)-ginsenoside Rg3 on induced hepatocellular carcinoma in rats].[Pubmed:15807271]
Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 Mar;36(2):217-20.
OBJECTIVE: To explore the anticarcinogenic mechanism of 20(R)-Ginsenoside Rg3 in induced liver tumor in SD rat. METHODS: Thirty-five SD rats with induced hepatocellular carcinoma were divided into a control group and 3 dosage groups according to the dosing levels of 20(R)-Ginsenoside Rg3. The tumour volume was measured by MR imaging. The apoptotic rat and S-phase fraction and diploid of tumor cell were measured with flow cytometry. Protein expression of PCNA and TNF were evaluated with immunohistochemistry. RESULTS: There was significant difference in tumour volume between the high dosage group and the control group. The average apoptotic rates were 11.08+/-3.78, 13.57+/-3.34, 27.35+/-16.04 and the S-phase fractions were 23.98+/-9.44, 19.73+/-6.62, 14.09+/-3.48 in the low-, medium-, and high-dosage groups respectively. The apoptotic rate was significantly higher in the high-dosage group than in the medium-dosage group and low-dosage group. Before-after comparison showed that the anti-proliferative effects of 20(R)-Ginsenoside Rg3 were significant in three treatment groups. The higher positive rats of protein expression with PCNA and TNF were significant difference in the high-dosage group compared to those in the low-dosage group. No significant difference between the medium-dosage group and the low-dosage group. CONCLUSION: 20(R)-Ginsenoside Rg3 can noticeably inhibit the proliferation of tumor cells, and efficaciously induce the apoptosis and facilitate necrosis of the tumor cells, and there appears to be a dose dependent effect.
Metabolism of 20(S)- and 20(R)-ginsenoside Rg3 by human intestinal bacteria and its relation to in vitro biological activities.[Pubmed:11824558]
Biol Pharm Bull. 2002 Jan;25(1):58-63.
When ginsenoside Rg3 was anaerobically incubated with human fecal microflora, all specimens metabolized ginsenoside Rg3 to ginsenoside Rh2 and protopanaxadiol. The main metabolite was ginsenoside Rh2. 20(S)-ginsenoside Rg3 was quickly transformed to 20(S)-ginsenoside Rh2 or 20(S)-protopanaxadiol in an amount 19-fold that compared with the transformation of 20(R)-Ginsenoside Rg3 to 20(R)-ginsenoside Rh2 or 20(R)-protopanaxadiol. Among the bacteria isolated from human fecal microflora, Bacteroides sp., Eubacterium sp., and Bifidobacterium sp. metabolized ginsenoside Rg3 to protopanaxadiol via ginsenoside Rh2. However, Fusobacterium sp. metabolized ginsenoside Rg3 to ginsenoside Rh2 alone. Among ginsenoside Rg3 and its metabolites, 20(S)-protopanaxadiol and 20(S)-ginsenoside Rh2 exhibited the most potent cytotoxicity against tumor cell lines, 20(S)- and 20(R)-protopanaxadiols potently inhibited the growth of Helicobacter pylori, and 20(S)-ginsenoside Rh2 inhibited H+/K+ ATPase of rat stomach.
The anti-fatigue effect of 20(R)-ginsenoside Rg3 in mice by intranasally administration.[Pubmed:18981567]
Biol Pharm Bull. 2008 Nov;31(11):2024-7.
20(R)-Ginsenoside Rg3 (20(R)-Rg3) has shown multiple pharmacological activities and been considered as one of the most promising approaches for fatigue treatment. However, 20(R)-Rg3 has a low bioavailability after oral administration in human due to the first-pass effect. Recently, nasal route has gained increasing interest as it can avoid first-pass effect for its lower enzymatic activity compared with the gastrointestinal tract and liver. In order to provide an animal experimental evidence of 20(R)-Rg3 intranasal administrated preparation, the anti-fatigue effect of 20(R)-Rg3 after intranasal administration was investigated. Two weeks after 20(R)-Ginsenoside Rg3 was administrated intranasally to mice at three different doses, the anti-fatigue effect of 20(R)-Rg3 was evaluated by the weight-loaded swimming test and biochemical parameters related to fatigue, such as serum urea nitrogen (SUN), lactic dehydrogenase (LDH), superoxide dismutase (SOD), malondialdehyde (MDA), blood lactic acid (LA) and hepatic glycogen. The results showed that compared with the negative control group, the intermediate-dose and the high-dose groups significantly prolonged the weight-loaded swimming time (p<0.05; p<0.01), and also increased the hepatic glycogen levels (p<0.05); SUN levels were decreased considerably in three 20(R)-Rg3-treated groups (p<0.01). In addition, the low-dose group obviously decreased the content of blood LA (p<0.05). However, the levels of LDH, SOD and MDA did not show a significant change. Our results predicted a benefit of 20(R)-Rg3 as an anti-fatigue treatment by intranasal administration. The mechanism was related to the increase of the storage of hepatic glycogen, and the decrease of the accumulation of metabolite such as lactic acid and serum urea nitrogen.
